Orazio Caffo
Karolinska University Hospital
Quality of lifeCancerInternal medicineSurgeryOncologyRetrospective cohort studyAbiraterone acetateLung cancerEnzalutamideChemotherapyCarcinomaCabazitaxelProstate cancerGemcitabineDocetaxelIn patientCastration resistantRadiation therapyBreast cancerMedicine
Publications 341
#1Antonello VecciaH-Index: 14
#2Vincenzo SforzaH-Index: 12
Last. Orazio CaffoH-Index: 36
view all 10 authors...
Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-small-cell lung cancer patients receiving pembrolizumab. Patients & methods: We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient, we evaluated 1-year overall survival (OS) and progression-free survival rate. C-statistic and survival receiver operating characteristic curves were used to study discrimination of LIP...
#1Alvise Berti (Mayo Clinic)H-Index: 17
#2Roberto BortolottiH-Index: 7
Last. Antonello VecciaH-Index: 14
view all 10 authors...
INTRODUCTION The introduction in clinical practice of the immune checkpoint inhibitors (ICIs) radically changed the treatment algorithm of lung cancers. To characterize the toxicity of ICIs (atezolizumab, durvalumab, nivolumab, pembrolizumab) is important for personalizing treatment. PATIENTS AND METHODS We performed a systematic review and meta-analysis of phase III randomized controlled trials assessing ICIs, from inception until April 23rd, 2020. We extracted the data from the ICI arm of each...
Italy was the first western country to be hit by the initial wave of severe adult respiratory syndrome coronavirus 2 pandemic, which has been more widespread in the country's northern regions. Early reports showing that cancer patients are more susceptible to the infection posed a particular challenge that has guided our Breast Unit at Hub Hospital in Trento to making a number of stepwise operational changes. New internal guidelines and treatment selection criteria were drawn up by a virtual mul...
#1Orazio CaffoH-Index: 36
#2Francesca MainesH-Index: 17
Last. Carlo MessinaH-Index: 15
view all 5 authors...
Introduction: Recently, there has been a paradigm shift in the treatment of advanced prostate cancer (PCa) because the approval of a number of new agents has significantly improved overall survival...
#1Orazio CaffoH-Index: 36
#2Viviana Frantellizzi (Sapienza University of Rome)H-Index: 13
Last. Giuseppe De Vincentis (Sapienza University of Rome)H-Index: 16
view all 26 authors...
Background: The retrospective studies that have so far described the outcomes of the sequential use of life-prolonging agents (LPAs) did not include metastatic castration-resistant prostate cancer (mCRPC) patients who received radium 223 (RA223) as part of their treatment. Consequently, it is not known whether including RA223 in the therapeutic sequence has an impact on cumulative survival. The aim of this study was to evaluate this impact by comparing the cumulative overall survival (OS) in two...
#1Alessandra Mosca (University of Eastern Piedmont)H-Index: 15
#2Ugo De GiorgiH-Index: 55
Last. Camillo Porta (UNIPV: University of Pavia)H-Index: 68
view all 12 authors...
OBJECTIVE Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials. METHODS Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers i...
#1Sara PilottoH-Index: 22
#2Isabella SperdutiH-Index: 52
Last. M. MilellaH-Index: 6
view all 20 authors...
#1Silvia NovelloH-Index: 72
#2Valentina MonicaH-Index: 16
Last. G. V. ScagliottiH-Index: 23
view all 35 authors...
#1T. Tony Cai (University of Oslo)H-Index: 77
#2Orazio CaffoH-Index: 36
Last. Truls E. Bjerklund Johansen (University of Oslo)H-Index: 24
view all 4 authors...